Flag­ship's Foghorn, part­nered with Mer­ck and Eli Lil­ly, gets a par­tial FDA hold af­ter pa­tient death

The FDA is tap­ping the brakes on a Flag­ship-backed biotech’s R&D ef­forts to de­vel­op a new treat­ment for blood can­cers af­ter a pa­tient died in an ear­ly-stage study.

Reg­u­la­tors is­sued a par­tial clin­i­cal hold to Foghorn Ther­a­peu­tics, the biotech an­nounced Thurs­day, press­ing pause on a Phase I dose-es­ca­la­tion study of a pro­gram known as FHD-286. Foghorn de­signed the drug to treat acute myeloid leukemia and myelodys­plas­tic syn­drome, and said the pa­tient’s death is pos­si­bly at­trib­ut­able to a con­di­tion known as dif­fer­en­ti­a­tion syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER